MAGIC Horizon

MAGIC Horizon

Biotechnology Research

Accelerating Development of Gene Therapies for Muscular Dystrophies

About us

The MAGIC (Next-generation Models And Genetic therapIes for rare neuromusCular diseases) consortium brings together leading international institutions and patient advocacy groups to accelerate the development of gene therapies for muscular dystrophies. By creating advanced human quasi vivo models, developing tissue-specific vectors, and exploring gene editing strategies, the consortium aims to overcome the barriers that have hindered the translation of genetic therapies into clinical applications. Through collaboration, innovation, and a patient-centred approach, the MAGIC consortium is committed to making a meaningful impact on the lives of individuals affected by muscular dystrophies.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
London
Type
Partnership
Founded
2023
Specialties
Muscular Dystrophies, Gene Therapy, Muscle-on-chip, Neuromuscular, and Bioengineering

Locations

Updates

Similar pages